Myelofibrotic transformation in essential thrombocythemia

Letters to the Editor Myelofibrotic Transformation in Essential Thrombocythemia. Author Reply

We thank Juergen Thiele and Hans Kvasnicka for commenting on our recently published paper including 605 patients with essential thrombocythemia (ET). We provided evidence that progression to myelofibrosis (postET MF) has a prevalence of 2.8% (10-year risk of 3.9%), and that progression to acute leukemia (AL) has a prevalence of 2.3% (10-year risk of 2.6%). The first question of Thiele and Kvasn...

Myelomegakaryoblastic transformation of essential thrombocythemia.

Essential thrombocytherrlia, considered one of the least common of the myeloproliferative disorders, is being diag nosed more frequently with the increasing use of automated blood cell counters. Essential thrombocythemia described by Epstein and Goendel in 1934 is a diagnosis of exclusion i.e., exclusion of all sy stemic conditions associated with thrombocytosis in an individual with a persiste...

Essential thrombocythemia

Essential thrombocythemia (ET) is an acquired myeloproliferative disorder (MPD) characterized by a sustained elevation of platelet number with a tendency for thrombosis and hemorrhage. The prevalence in the general population is approximately 30/100,000. The median age at diagnosis is 65 to 70 years, but the disease may occur at any age. The female to male ratio is about 2:1. The clinical pictu...

Thrombospondin in essential thrombocythemia.

Essential thrombocythemia is a myeloproliferative disorder characterized by frequent bleeding and thrombotic complications. On a molecular level, two abnormalities of platelet thrombospondin have been identified: abnormal glycosylation of the intact 185,000-dalton chain has been detected and a shortened form of the thrombospondin chain is present. We have used two monoclonal antibodies and Lens...

Ruxolitinib for essential thrombocythemia?